Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway

[1]  R. Levine,et al.  Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor. , 2019, Blood advances.

[2]  F. Couch,et al.  Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2 , 2019, Nature Communications.

[3]  I. Hickie,et al.  Homologous recombination DNA repair defects in PALB2-associated breast cancers , 2019, npj Breast Cancer.

[4]  Anna L. Brown,et al.  Genomic subtyping and therapeutic targeting of acute erythroleukemia , 2019, Nature Genetics.

[5]  R. Rosell,et al.  Association of PALB2 Messenger RNA Expression with Platinum‐Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  G. Castellani,et al.  Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery , 2018, Cancer.

[7]  A. Monteiro,et al.  The Role of PALB2 in the DNA Damage Response and Cancer Predisposition , 2017, International journal of molecular sciences.

[8]  Siraj M. Ali,et al.  Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition. , 2017, JCO precision oncology.

[9]  L. Bullinger,et al.  Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells , 2017, The Journal of clinical investigation.

[10]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[11]  A. Jakubowska,et al.  Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. , 2015, The Lancet. Oncology.

[12]  H. Pospiech,et al.  Heterozygous mutations in PALB2 cause DNA replication and damage response defects , 2013, Nature Communications.

[13]  Manuel Hidalgo,et al.  Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.

[14]  A. Einstein,et al.  Inside out , 1991, Nature.